Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,767 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Refractory Malignancy Clear all

Conditions: Prostate Cancer
Interventions: Nilutamide, Dasatinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Durham, North Carolina • Portland, Oregon • Seattle, Washington

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvocidib, cisplatin, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma
Interventions: aldesleukin, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: HDP-101; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more

Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Rituximab; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: T Cell Lymphoma
Interventions: Sorafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma
Interventions: rituximab; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions: brentuximab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 15
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 11 more

Conditions: Cancer
Interventions: aprepitant, dexamethasone, ondansetron, placebo; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastrointestinal Cancer
Interventions: Everolimus, Tivozanib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Interventions: Pixatimod, Nivolumab, Cyclophosphamide (low dose); Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma
Interventions: Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Providence, Rhode Island

Conditions: Head and Neck Cancer
Interventions: AuroLase Therapy; Device
Lead sponsor: Nanospectra Biosciences, Inc.; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Goodyear, Arizona • Houston, Texas

Conditions: T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions: Ibrutinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Leukemia, Myeloproliferative Diseases
Interventions: Clofarabine, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
Interventions: CD19.CAR-aNKT cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Laboratory Biomarker Analysis, Quality-of-Life Assessment, Simvastatin; Other · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic Lymphocytic Leukemia
Interventions: ISF35; Biological
Lead sponsor: Memgen, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Prostatic Neoplasms
Interventions: GM-CSF, Ketoconazole, Mitoxantrone; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study; Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more

Conditions: Hormone-Refractory Prostate Cancer
Interventions: Zoledronic acid, Estramustine, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate